ProCE Banner Activity

Antibody‒Drug Conjugates and Their Role in TROP2-Expressing Tumors


Download this slideset from a live CCO symposium for nurses to get an introduction to the TROP2 ADCs sacituzumab govitecan and datopotamab deruxtecan.

Released: April 28, 2023



Neelima Vidula

Neelima Vidula, MD

Assistant Professor of Medicine
Harvard Medical School
Attending Physician
Department of Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.